FDA approves CAR-T cell therapy Tecartus for relapsing refractive lymphoma.
-
Last Update: 2020-07-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Auto, a unit of !---- gides Al-Gilead Sciences, recently announced that the FDA has approved CAR-T cell therapy Tecartus (also known as KTE-X19) for the treatment of recurrent refractive lymtocyte lymphoma (MCL), the first CAR-T cell therapy approved for the treatment of MCLGilead's first CAR-T cell therapy approved in the U.Sis Yescarta, which was approved by the FDA in 2017 for patients with large B-cell lymphomaThe FDA's decision is based on the latest findings from the ZUMA-2 study, which recruited 74 patients who had received chemotherapy for pyridox, phenydamostin, anti-CD20 antibody therapy and BTK inhibitorsThe results showed that 87% of the 60 assessable patients responded to Tecartus infusions, and 62% of them received full remissionTecartus has a boxed warning that indicates the risk of cytokine release syndrome and nervous system toxicityThe FDA also asked Kite to conduct post-market observation studies on the treatmentKite noted that in the ZUMA-2 trial, the company's average time from leukocyte isolation to delivery was 15 days, with a manufacturing success rate of 96%
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
